SL
SLXN.US Silexion Therapeutics Corp
- Market cap
- USD 1.07M
- P/E
- -
- P/B
- 28.93x
- ROE
- -396.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SLXN.US undervalued?
Graham numberThe Graham number of Silexion Therapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Silexion Therapeutics Corp fundamental analysis
No fundamental analysis for Silexion Therapeutics Corp yet.
Silexion Therapeutics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Silexion Therapeutics Corp
Silexion Therapeutics Corp operates as a clinical-stage oncology-focused biotechnology company. It engages in the development of treatments for unsatisfactorily treated solid tumor cancers. The company is advancing its lead product candidate, SIL204, a small interfering RNA (siRNA) through Phase 2/3 clinical evaluation. It focuses on therapeutic advancements in the field of oncology, as well as developing its lead product candidate for pancreatic cancer. The company was foun…
Full company profileSilexion Therapeutics Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Silexion Therapeutics Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | - | - | - | - | -25.0K | -14.0K | - |
| Operating Income | - | -196K | -944K | -3.86M | -4.68M | -12.6M | 11.6M | -12.2M |
| EBITDA | - | -196K | -755K | -3.32M | -5.02M | -16.5M | -11.9M | -11.9M |
| Net Income | - | -196K | -755K | -3.22M | -4.94M | -16.4M | -11.9M | -11.8M |
| EPS | - | -18 | -69 | -6,914 | -159,419 | -95,046 | -2,150 | -64 |
| Balance Sheet | ||||||||
| Total Assets | - | 129K | 115M | 9.33M | 5.26M | 2.86M | 7.22M | 6.83M |
| Total Liabilities | - | 299K | 509K | 16.4M | 17.3M | 6.85M | 4.61M | 3.86M |
| Shareholders' Equity | - | -170K | 115M | -10.7M | -15.5M | -3.99M | 2.60M | 2.97M |
| Cash & Short-term Investments | - | 51.7K | 38.9K | 8.26M | 4.60M | 1.19M | 5.99M | 4.76M |
| Total Debt | - | - | - | 271K | 171K | 4.49M | 468K | 374K |
| Cash Flow | ||||||||
| Operating Cash Flow | -911K | -75.0K | -1.41M | -3.34M | -4.53M | -8.40M | -10.8M | -11.6M |
| Capital Expenditure | 3.00K | 0.00 | 4.00 | 40.0K | 12.0K | 22.0K | 9.00K | 56.0K |
| Free Cash Flow | - | -75.0K | -1.41M | -3.38M | -4.54M | -8.42M | -10.8M | -11.6M |
| Ratios | ||||||||
| ROE | - | - | -0.7% | - | - | - | -457.6% | -396.1% |
| ROA | - | -151.4% | -0.7% | -34.4% | -94.0% | -574.3% | -165.1% | -172.2% |
| Debt to Equity | - | - | - | - | - | - | 0.18x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Silexion Therapeutics Corp dividends
Silexion Therapeutics Corp has not paid dividends in the last 7 fiscal years.
Last stock split: 1:24 on Nov 11, 2026.
Who owns Silexion Therapeutics Corp
- Insiders 13.62%
- Institutions 5.46%
- Public & others 80.91%
- Shares outstanding 650K
- Free float 231K
Top institutions holding SLXN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 15.2K | 0.11% | 0.00% | Jun 2026 |
| UBS Group AG | 1.41K | 0.01% | +2,613.46% | Jun 2026 |
| A. Montag & Associates Inc | 300.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 76.00 | 0.00% | 0.00% | Jun 2026 |
| Pflug Koory, LLC. | 33.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 2.00 | 0.00% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Silexion Therapeutics Corp company profile
- Company name
- Silexion Therapeutics Corp
- Ticker
- SLXN.US
- ISIN
- KYG1281K1638
- Exchange
- USA Stocks
- Listed since
- Aug 16, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- 12 Abba Hillel Road, Ramat Gan, Israel, 5250606
- Phone
- 972 3 756 4999
- Website
- silexion.com
About Silexion Therapeutics Corp
Silexion Therapeutics Corp operates as a clinical-stage oncology-focused biotechnology company. It engages in the development of treatments for unsatisfactorily treated solid tumor cancers. The company is advancing its lead product candidate, SIL204, a small interfering RNA (siRNA) through Phase 2/3 clinical evaluation. It focuses on therapeutic advancements in the field of oncology, as well as developing its lead product candidate for pancreatic cancer. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.
Silexion Therapeutics Corp management
3- Mr. Ilan Hadar M.B.A.Chairman & CEO · born 1969
- Ms. Mirit Horenshtein HadarEVP of Finance Affairs, CFO & Secretary · born 1984
- Dr. Mitchell Shirvan M.B.A., Ph.D.Chief Scientific & Development Officer · born 1954